Trials / Completed
CompletedNCT02558465
Special Drug Use Investigation of Xarelto for Venous Thromboembolism (VTE)
Special Drug Use Investigation of Xarelto for VTE
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 2,540 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The objective of this investigation is to assess safety and effectiveness of Xarelto under practice routine use in VTE secondary prevention after acute DVT, focusing on hemorrhagic-related AEs, recurrent venous thromboembolism (PE/DVT), all-cause mortality. This study is a company sponsored, one- arm prospective cohort study with patients to whom Rivaroxaban treatment for VTE (PE/DVT) has been chosen. The study includes a standard observation period (1 year) and an extension survey period (2 years, at the longest).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rivaroxaban (Xarelto, BAY59-7939) | Treatment parameters following the summary of product characteristics and the physician's decision |
Timeline
- Start date
- 2015-11-13
- Primary completion
- 2021-04-01
- Completion
- 2021-05-31
- First posted
- 2015-09-24
- Last updated
- 2022-11-01
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT02558465. Inclusion in this directory is not an endorsement.